PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Venook, Alan P.
TI  - Outcomes Similar with BEV or CET Added to Induction CT for mCRC
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 17--17
VI  - 14
IP  - 22
4099  - http://mdc.sagepub.com/content/14/22/17.1.short
4100  - http://mdc.sagepub.com/content/14/22/17.1.full
AB  - First-line treatment for metastatic colorectal cancer (mCRC) is combination chemotherapy (CT) plus a monoclonal antibody (mAB). The Cetuximab and/or Bevacizumab Combined With Combination Chemo—therapy in Treating Patients With Metastatic Colorectal Cancer [CALGB/SWOG 80405; NCT00265850] study examined whether a strategy that blocked endothelial growth factor receptors with the mAB cetuximab (CET) or blocked vascular endothelial growth factors with the mAB bevacizumab (BEV) provided a greater improvement in the effectiveness of CT.